MannKind initiated with Outperform on growing portfolio at Wedbush

Wedbush last night initiated coverage of MannKind with an Outperform rating and $10 price target. The analyst says the company’s growing portfolio can “drive meaningful value” over the rest of the decade and beyond. MannKind’s orphan lung and endocrine product portfolio offers the potential for “real future value-creation and optionality,” the analyst tells investors in a research note. The firm expects strong patient demand and increased manufacturing capacity at MannKind’s facility to support long-term growth.